Open AccessGenome‐wide DNA methylome analysis reveals methylation subtypes with different clinical outcomes for acute myeloid leukemia patients
Author(s) -
Gao Haiyan,
He Xin,
Li Qiang,
Wang Ying,
Tian Yaoyao,
Chen Xi,
Wang Jinghua,
Guo Yan,
Wang Wei,
Li Xiaoyun
Publication year - 2020
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.3291
Subject(s) - myeloid leukemia , dna methylation , methylation , cpg site , biology , leukemia , oncology , cancer research , gene , bioinformatics , medicine , genetics , gene expression
Leukemia is the second common blood cancer after lymphoma, and its incidence rate has an increasing trend in recent years. Acute myeloid leukemia (AML) is one of the prevalent forms of leukemia. Although previous studies have investigated the methylation profile for AML patients, the AML methylation subtypes based on the genome‐wide methylome are still unclear. In the present study, we identified three methylation subtypes for AML samples based on the methylation profiles at CGI, CGI shore, CGI shelf, and opensea genomic contexts. Analyzing the molecular characteristics and clinical factors of the three subtypes revealed different methylation patterns and clinical outcomes between them. Further analysis revealed subtype dependent marker genes and their promoter CpG sites with regulatory function. Finally, we found that combining the AML patient age and methylation pattern brought better clinical outcome classification. In conclusion, we identified AML methylation subtypes and their marker genes, these results may help to excavate potential targets for clinical therapy and the development of precision medicine for AML patients.